A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has expanded significantly.
• Multiple classes of agents, including immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors, and monoclonal antibodies, are available.
• Each agent class offers distinct mechanisms of action, efficacy, and safety profiles.

Purpose of the Study:

• To provide an overview of available treatment options for RRMM.
• To discuss the efficacy and safety profiles of different agent classes and combination regimens.
• To focus on tailoring treatment strategies for specific patient populations.

Main Methods:

• Review of current literature on RRMM treatment.
• Analysis of mechanisms of action, efficacy, and safety data for various therapeutic agents.
• Examination of treatment approaches for distinct patient subgroups.

Main Results:

• The complexity of treatment selection for RRMM has increased with the availability of diverse therapeutic options.
• Optimal treatment choice requires consideration of both patient-related and disease-related factors.
• Specific treatment guidelines for elderly patients, those with high-risk cytogenetics, or refractory disease remain to be fully defined.

Conclusions:

• Personalized treatment strategies are crucial for maximizing clinical benefit and minimizing toxicity in RRMM.
• Physicians must carefully weigh multiple criteria when selecting therapies for patients with RRMM.
• Further research is needed to define optimal treatment pathways for specific patient populations within the evolving RRMM treatment landscape.